Tags

Type your tag names separated by a space and hit enter

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.
J Immunol. 2020 Jul 15; 205(2):307-312.JI

Abstract

The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.

Links

PMC Free PDF

Authors+Show Affiliations

Yap JKY
School of Postgraduate Studies, International Medical University, 57000 Kuala Lumpur, Malaysia.
Moriyama M
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Iwasaki A
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520; akiko.iwasaki@yale.edu. Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06512; and. Howard Hughes Medical Institute, Chevy Chase, MD 20815.

MeSH

AnimalsAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsHumansImmunity, InnateInflammasomesIntercellular Signaling Peptides and ProteinsMacrophages, AlveolarPandemicsPneumonia, ViralPyroptosisSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Signal TransductionCOVID-19 Drug Treatment

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

32493814

Citation

Yap, Jeremy K Y., et al. "Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19." Journal of Immunology (Baltimore, Md. : 1950), vol. 205, no. 2, 2020, pp. 307-312.
Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. J Immunol. 2020;205(2):307-312.
Yap, J. K. Y., Moriyama, M., & Iwasaki, A. (2020). Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. Journal of Immunology (Baltimore, Md. : 1950), 205(2), 307-312. https://doi.org/10.4049/jimmunol.2000513
Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. J Immunol. 2020 Jul 15;205(2):307-312. PubMed PMID: 32493814.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. AU - Yap,Jeremy K Y, AU - Moriyama,Miyu, AU - Iwasaki,Akiko, Y1 - 2020/06/03/ PY - 2020/5/6/received PY - 2020/5/15/accepted PY - 2020/6/5/pubmed PY - 2020/7/15/medline PY - 2020/6/5/entrez SP - 307 EP - 312 JF - Journal of immunology (Baltimore, Md. : 1950) JO - J Immunol VL - 205 IS - 2 N2 - The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases. SN - 1550-6606 UR - https://www.unboundmedicine.com/medline/citation/32493814/Inflammasomes_and_Pyroptosis_as_Therapeutic_Targets_for_COVID_19_ DB - PRIME DP - Unbound Medicine ER -